Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1686 articles with Sanofi (France)
-
Sanofi to Cut 670 Jobs in France by 2020
12/6/2018
Some French employees of drug giant Sanofi will receive an unwanted Christmas present this year – pink slips. The company will lay off 670 employees in France on what has been reported as a “voluntary basis.” -
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
-
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.
-
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
11/21/2018
There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundat... -
AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi for $1.5 Billion
11/14/2018
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion. -
Researchers at the University of California, San Diego (UCSD) ran successful animal studies of a gene therapy that appeared to cure a disease in mice similar to amyotrophic lateral sclerosis (ALS), sometimes also known as Lou Gehrig’s Disease.
-
To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.
-
Nearly two weeks after the U.S. Food and Drug Administration approved Sanofi and Regeneron’s Dupixent as an add-on maintenance therapy for moderate to severe asthma, the France-based company reported a surge in sales for the medication in its most recent quarterly report.
-
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
-
The FDA approved Sanofi and Regeneron’s Dupixent (dupilumab) as an add-on maintenance therapy for patients with moderate-to-severe asthma. The approved group is age 12 years and older with either an eosinophilic phenotype or with an oral corticosteroid-dependent asthma.
-
This week will have moderate activity by the U.S. Food and Drug Administration (FDA). Although they jumped the gun on Regeneron and Sanofi’s cancer drug, there are still plenty of other decisions being made this week. Here’s a look.
-
Immune Design Abandons Cancer Vaccine Program, Drops 20% of Workforce at Two U.S. Locations
10/18/2018
The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program. -
The Price Is Wrong: Minnesota AG Sues Three Companies That Control 99% of World's Insulin
10/17/2018
The Minnesota Attorney General is calling out Sanofi-Aventis, Novo Nordisk and Eli Lilly over alleged price gouging for insulin. This week Minnesota Attorney General Lori Swanson filed a lawsuit against the three companies over insulin price hikes. -
Shares of Regeneron jumped more than 5 percent Monday after the company announced that its blockbuster drug Dupixent (dupilumab) hit the mark in two Phase III trials studying the drug as a treatment for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps.
-
Two well-established pharma companies are expanding in two different U.S. cities. One city is known for the plethora of pharma and biotech jobs, while the other is in an area that might not immediately spring to mind when it comes to biotech hubs.
-
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
-
NIH Awards Grant to Battle Sepsis to San Diego's Allele Biotechnology and Pharmaceuticals
10/15/2018
The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded Allele Biotechnology and Pharmaceuticals a Small Business Innovative Research grant to develop therapies for sepsis. -
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
-
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
-
Earlier this month, Novo Nordisk announced it was laying off 400 staffers in Denmark and China. Today, Reuters reports that the Danish company plans to lay off about 250 people in the United States.